Skip Navigation


NDT Plus Advance Access originally published online on January 4, 2008
NDT Plus 2008 1(2):94-96; doi:10.1093/ndtplus/sfm032
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/2/94    most recent
sfm032v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Navaneethan, S. D.
Right arrow Articles by Sloand, J.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Pseudo-anion gap acidosis

Sankar D. Navaneethan1, Robert Mooney2 and James Sloand1

1 Division of Nephrology, University of Rochester School of Medicine, Rochester, NY, USA
2 Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine, Rochester, NY, USA

Correspondence: Sankar D. Navaneethan, Department of Medicine, Nephrology Division, University of Rochester School of Medicine, Rochester, NY, USA. Tel: +1-585-319-6129; Fax: +1-585-442-9201; E-mail: Sankar_navaneethan{at}urmc.rochester.edu

Key Words: acidosis • anion gap

Received for publication October 5, 2007. Accepted for publication November 30, 2007.


    Case
 Top
 Case
 References
 
A 74-year-old Caucasian male was referred to our clinic for low serum bicarbonate levels and a high anion gap (HAG). Past medical history included hypertension, hypothyroidism, iron deficiency anaemia secondary to gastrointestinal bleeding and hyperlipidaemia. He was on Bicitra 30 mL orally three times daily, levothyroxine 75 mcg daily, atorvastatin 10 mg daily, ferrous sulphate 324 mg daily and chlorthalidone 12.5 mg daily. He denied smoking, alcoholism or illegal drug abuse. Physical exam was unremarkable.

His laboratory values obtained over the 18 months after our evaluation are outlined in Table 1. Arterial blood gas showed a pH of 7.37, PCO2 of 35 mmHg and PO2 of 87 mmHg when the serum HCO3- level was 12 mEq/L. Serum lactate levels on several occasions were <2.2 mmol/L. Serum ketones were negative and the beta-hydroxybutyrate level was mildly elevated at 3.60 mg/dL (normal 0–3.0 mg/dL). Salicylate level was <1 mg/dL. D-Lactate levels were immeasurable. Thiamine levels were normal. A serum and urine protein electrophoresis did not reveal any paraproteinaemia. Urinalysis revealed a specific gravity of 1.020, pH 6.0 with negative protein and blood by dipstick. Urine toxicology screens for ethanol, methanol, ethylene glycol and isopropanol were negative. His urine organic acid profile was normal and no 5-oxoproline was detected. He was started on various forms of bicarbonate supplementation and atorvastatin was stopped, but neither bicarbonate levels nor anion gap changed significantly (Table 1).


View this table:
[in this window]
[in a new window]

 
Table 1 Laboratory results of our patient over 18 months

 
In the absence of any apparent explanation for a decrease in serum bicarbonate with an HAG despite extensive work-up, we questioned the validity of the laboratory testing.

As such, venous blood was drawn from the patient into a heparinized tube, with equal aliquots taken for enzymatic measurement of bicarbonate [1] and indirect measurement utilizing reference electrode assessment of pH and carbon dioxide, followed by logarithmic calculation of the bicarbonate level [2]. The HCO3- level by the former was 10 mEq/L. Blood gas technology provided a venous HCO3- measurement of 31 mEq/L with a pH of 7.43, PO2 of 78 mmHg and PCO2 of 46 mmHg. Multiple repeat measurements confirmed this finding.

To assess the possibility of an endogenous inhibitor or interfering substance, a sample of the patient's serum (7.7 mEq/L bicarbonate by an enzymatic method) was sequentially diluted with either a normal serum (25.6 mEq/L bicarbonate) or a commercial bicarbonate solution (31.9 mEq/L). Bicarbonate values were determined by the enzymatic method and compared to the predicted content of bicarbonate in the admixtures. Recovery of bicarbonate was at least 85–90% at all dilutions (Figure 1). This does not support the presence of an excess soluble inhibitor, since the patient's serum did not significantly affect detection of bicarbonate in admixtures. Conversely, recoveries did not rise above 100%, indicating that suppression of the patient's bicarbonate measurement was not due to a weak or low concentration inhibitor that could be overcome with dilution.


Figure 1
View larger version (14K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 1 Admixtures of the affected patient serum with other bicarbonate sources yield predicted bicarbonate levels. Aliquots of affected serum (7.7 mEq/L) were mixed with either a bicarbonate solution (31.9 mEq/L) or a normal serum (25.6 mEq/L) at the indicated percentages. Measured bicarbonate levels in the admixtures were plotted together with the predicted bicarbonate values in the admixtures calculated from the sum of the individual component contributions.

 
It has been reported that the calculated bicarbonate method has a positive bias relative to the enzymatic method [3,4]. To determine the magnitude of this bias in our laboratory, 88 pairs of patient results for both calculated and enzymatic bicarbonate were compared. As shown in Figure 2, a positive bias of 1.7 mEq/L was observed. This is in close agreement with a positive bias of 1.6 mEq/L that was reported by Story et al. [3]. While a positive bias in the calculated bicarbonate is observed, it is very unlikely that our patient's observed difference of 21 mEq/L between the calculated and enzymatic methods is explained by this methodologic bias.


Figure 2
View larger version (14K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 2 Bland–Altman plot of the difference between calculated bicarbonate and enzymatic measurement of serum bicarbonate. Data represent a series of 88 paired patient data sets of calculated bicarbonate, derived from the Henderson–Hasselbalch equation applied to arterial blood gas parameters and a matched serum bicarbonate measurement. Units are mEq/L. Solid line represents the mean difference or bias of 1.7 mEq/L. Several data points are superimposed.

 
The underlying source of HAG acidosis is usually detected based on the clinical scenario and the basic laboratory test results [5]. Apart from the common causes of metabolic acidosis, several cases of HAG acidosis due to rhabdomyolysis, hyperphosphataemia, toluene poisoning, thiamine deficiency, statins, D-lactic acidosis, accumulation of Kreb cycle intermediates such as citrate and isocitrate, acetaminophen toxicity or 5-oxoprolinase deficiency and propylene glycol have been reported [5–9]. We excluded the above-mentioned possible causes of HAG metabolic acidosis, with appropriate blood and urine tests.

Lowering of the serum bicarbonate level without any alteration in other elements of the chemistry profile will de facto result in an apparent widening of the normal anion gap by pure mathematical means. The resulting diagnosis of an HAG metabolic acidosis is contingent upon valid bicarbonate measurement. Factitious reduction in laboratory measures of serum bicarbonate levels due to interfering substances or serum-specific factors has, to our knowledge, never been reported.

The inhibition of serum bicarbonate in this case does not appear to be due to an excess of a soluble inhibitor or interfering substance. The suppression of bicarbonate quantitation was neither reversed by dilution nor transferred to a mixture of patient serum with a second source of bicarbonate. The patient's bicarbonate appears to be at least partially inaccessible to the enzyme reactions in the bicarbonate assay, yet accountable in the indirect calculation using the Henderson–Hasselbach equation. At this time, the nature of the inhibition remains unknown.

Clinicians depend upon the veracity of the assay for serum bicarbonate to make accurate assessment of acid–base disturbances. As demonstrated here, factitious reduction in serum HCO3- levels coupled with an HAG can occur and should be a consideration in an otherwise healthy-appearing individual in whom organic acids are not present in excess.

Conflict of interest statement. None declared.


    References
 Top
 Case
 References
 

  1. Norris KA, Atkinson AR, Smith WG. Colorimetric enzymatic determination of serum total carbon dioxide, as applied to the vickers multichannel 300 discrete analyzer. Clin Chem (1975) 21:1093–1101.[Abstract]
  2. Severinghaus JW, Bradley AF. Electrodes for blood pO2 and pCO2 determination. J Appl Physiol (1958) 13:515–520.[Free Full Text]
  3. Story DA, Poustie S. Agreement between two plasma bicarbonate assays in critically ill patients. Anaesth Intensive Care (2000) 28:399–402.[Web of Science][Medline]
  4. Story DA, Poustie S, Bellomo R. Comparison of three methods to estimate plasma bicarbonate in critically ill patients: Henderson– Hasselbalch, enzymatic, and strong-ion-gap. Anaesth Intensive Care (2001) 29:585–590.[Web of Science][Medline]
  5. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol (2007) 2:162–174.[Abstract/Free Full Text]
  6. Fenves AZ, Kirkpatrick HM, Patel VV, et al. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol (2006) 1:441–447.[Abstract/Free Full Text]
  7. Forni LG, McKinnon W, Lord GA, et al. Circulating anions usually associated with the Kreb cycle in patients with metabolic acidosis. Crit Care (2005) 9:R591–R595.[CrossRef][Web of Science][Medline]
  8. Romanski SA, McMahon MM. Metabolic acidosis and thiamine deficiency. In: Mayo Clin Proc (1999) 74:259–263.[Abstract]
  9. Neale R, Reyonlds TM, Saweirs. Statin precipitated lactic acidosis? J Clin Path (2004) 57:989–990.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/2/94    most recent
sfm032v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Navaneethan, S. D.
Right arrow Articles by Sloand, J.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?